Market closed
Terns Pharmaceuticals/$TERN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Terns Pharmaceuticals
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
Ticker
$TERN
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
59
Website
TERN Metrics
BasicAdvanced
$210M
-
-$1.12
-0.31
-
Price and volume
Market cap
$210M
Beta
-0.31
52-week high
$10.03
52-week low
$1.87
Average daily volume
1.2M
Financial strength
Current ratio
23.138
Quick ratio
22.886
Long term debt to equity
0.266
Total debt to equity
0.389
Management effectiveness
Return on assets (TTM)
-20.13%
Return on equity (TTM)
-29.56%
Valuation
Price to book
0.6
Price to tangible book (TTM)
0.6
Price to free cash flow (TTM)
-2.724
Growth
Earnings per share change (TTM)
-11.72%
3-year earnings per share growth (CAGR)
-20.32%
What the Analysts think about TERN
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Terns Pharmaceuticals stock.
TERN Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TERN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TERN News
AllArticlesVideos
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewsWire·2 weeks ago
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
GlobeNewsWire·4 weeks ago
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Terns Pharmaceuticals stock?
Terns Pharmaceuticals (TERN) has a market cap of $210M as of April 20, 2025.
What is the P/E ratio for Terns Pharmaceuticals stock?
The price to earnings (P/E) ratio for Terns Pharmaceuticals (TERN) stock is 0 as of April 20, 2025.
Does Terns Pharmaceuticals stock pay dividends?
No, Terns Pharmaceuticals (TERN) stock does not pay dividends to its shareholders as of April 20, 2025.
When is the next Terns Pharmaceuticals dividend payment date?
Terns Pharmaceuticals (TERN) stock does not pay dividends to its shareholders.
What is the beta indicator for Terns Pharmaceuticals?
Terns Pharmaceuticals (TERN) has a beta rating of -0.31. This means that it has an inverse relation to market volatility.